If you are a woman over 45 who has been quietly struggling with weight gain that does not respond to the things that used to work- eating less, moving more, cutting out the obvious things- you are not imagining it, and you are not failing. Something has genuinely changed in your body, and the clinical world is only now catching up with what that means for treatment.
GLP-1 receptor agonists, medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), are being prescribed to women over 45 at a rapidly increasing rate. Not because they want a shortcut. Because they are dealing with insulin resistance, metabolic dysfunction, and a hormonal environment that has fundamentally altered how their body processes food, stores fat, and responds to exercise.
At Soteria Pilates in Maitland, this is one of the most common conversations we have with new clients. This post explains what is happening physiologically during perimenopause and menopause, why GLP-1s address some of those mechanisms, and, critically, what they do not do, and why Pilates-based strength training is not optional alongside them.
What Perimenopause Actually Does to Your Metabolism
Perimenopause, the transition phase that typically begins in the early to mid-40s, sometimes earlier, is not simply a hormonal event. It is a systemic metabolic shift. Oestrogen does not only regulate the reproductive cycle. It plays a central role in how the body uses insulin, where it stores fat, how effectively it builds and maintains muscle, and how the brain regulates hunger and satiety.
As oestrogen levels begin to fluctuate and eventually decline, several things happen simultaneously. Insulin sensitivity decreases, meaning the body needs more insulin to manage the same amount of blood glucose, and excess glucose is more readily converted to fat. The distribution of that fat shifts, moving from the hips and thighs toward the abdomen, which is metabolically more active and more closely linked to cardiovascular and inflammatory risk.
Resting metabolic rate declines. Lean muscle mass, which is the body’s primary engine for burning calories at rest, begins to decrease more rapidly from around age 40, a process called sarcopenia. And the brain’s regulation of appetite becomes less reliable: the hormonal signals that communicate fullness and hunger become less consistent, making overeating easier and satiety harder to read.
The result, for many women, is a body that gains weight on the same calories it used to maintain weight on, loses muscle faster than it can rebuild it, stores fat in new and more health-relevant places, and does not respond to conventional diet and exercise the way it did at 35. This is not a motivation problem. This is physiology.
“There is no prize for struggling. If your body has changed, the tools have to change with it.”
Why GLP-1s Are Clinically Relevant for This Population
GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed for type 2 diabetes management. Their mechanism, stimulating insulin secretion in response to food, suppressing glucagon, slowing gastric emptying, and acting on the brain’s appetite regulation centres, addresses several of the exact mechanisms that go wrong during the menopausal metabolic shift.
For women with insulin resistance, which is increasingly common in perimenopause even without a formal diabetes diagnosis, GLP-1s can improve insulin sensitivity, reduce fasting glucose, and make the body’s metabolic response to food more functional. For women whose appetite regulation has become dysregulated, where hunger signals are more persistent, and satiety signals arrive later or not at all, GLP-1s act centrally to restore a more normal relationship between eating and fullness.
This is why the prescription rate among women in their 40s and 50s has increased so significantly. It is not lifestyle vanity. It is a clinical recognition that the metabolic changes of menopause create a physiological environment that dietary intervention alone frequently cannot correct, particularly in women with complicating factors like autoimmune conditions, polycystic ovary syndrome (PCOS) that has persisted into midlife, or a history of disordered eating that has disrupted regulation over time.
The medication works. For the right person, in the right clinical context, it addresses real physiological problems and produces meaningful health improvements beyond weight loss alone: reductions in inflammatory markers, improved cardiovascular risk profiles, and better glycaemic control.
What GLP-1s Do Not Do, and Why That Matters
GLP-1 medications reduce appetite and support weight loss. They do not build muscle. They do not protect bone density. They do not prevent the accelerated sarcopenia that accompanies both ageing and significant caloric restriction. In fact, without deliberate resistance training, the weight that comes off on a GLP-1 is not exclusively fat. Studies consistently show that between 25 and 40 percent of weight lost during rapid weight loss, pharmacologically driven or otherwise, can be lean muscle mass.
For a woman over 45 who is already experiencing age-related muscle loss, losing additional muscle during a GLP-1 programme is not a cosmetic concern. It is a functional and metabolic one. Less muscle means a slower resting metabolism, making weight regain more likely if the medication is stopped. It means reduced bone protection, weaker joints, and a measurably lower capacity for independent physical function as the years progress.
The goal of a GLP-1 programme for a woman in this life stage should not simply be to weigh less. The goal should be to become metabolically healthier and physically stronger, and only one of those outcomes is delivered by the medication itself.
The Role of Pilates Strength Training Alongside GLP-1 Treatment
Pilates-based strength training is not the obvious pairing for a GLP-1 programme in the public conversation: that space tends to be occupied by general advice to ‘do some exercise.’ But for women over 45 specifically, it addresses the precise combination of needs that this population has.
It provides progressive resistance loading: the mechanical stimulus that signals the body to retain and build muscle, and that drives bone remodelling to protect density at the spine, hip, and wrist. It is joint-protective, which matters when joints are under additional stress from both weight loss and the connective tissue changes that accompany declining oestrogen. It is scalable to the injection cycle, so that lower-energy days post-injection do not derail the programme. And it rebuilds the deep postural and functional strength that everyday physical capability depends on.
At Soteria Pilates in Maitland, our reformer, chair, and mat-based programmes are designed specifically around this need: progressive load delivered in a format that is forgiving on lower-energy days and consistent enough to produce real change over time.
Two to three sessions per week of properly programmed Pilates-based strength training, paired with adequate protein intake (0.7 to 1g per pound of bodyweight daily), is the combination the evidence points to for preserving lean mass during GLP-1-driven weight loss. Neither element works as well without the other.
Insulin Resistance, Exercise, and the Feedback Loop
There is a direct and well-established relationship between resistance training and insulin sensitivity. Muscle tissue is the body’s primary site of glucose uptake. When muscle mass increases, or is maintained, the body’s capacity to manage blood glucose improves, meaning the insulin resistance that drove the GLP-1 prescription in the first place is being addressed from two directions simultaneously: pharmacologically by the medication, and physiologically by the training.
This matters for women who are using GLP-1s as a bridge: a tool to address the metabolic dysfunction of perimenopause while building the physical foundations that make long-term health sustainable. The medication can be a beginning. Strength training is what makes the improvement last.
Starting the Conversation With Your Prescribing Clinician
If you are currently on a GLP-1 or considering one, there are questions worth raising that often do not get asked in a standard prescription appointment. Has your muscle mass been measured? Has your bone density been assessed? What is the plan for resistance training alongside the medication? What happens to your metabolic rate if the medication is eventually reduced or stopped?
These are not anxious questions. They are the questions of someone who wants the outcome to be lasting, not just immediate. A GLP-1 prescription without a strength training and nutrition plan is an incomplete intervention, and for women over 45 navigating the compounding effects of menopause, the stakes of getting that right are high enough to be worth the conversation.
Conclusion
The rise in GLP-1 prescriptions among women over 45 is not a trend. It is a clinical response to a genuine and widely underserved physiological problem. The medication addresses real mechanisms. The gap, the part that requires active choice, is building the physical foundation that makes the outcome worth having.
If you are on a GLP-1 and no one has spoken to you about strength training, protein, or bone health, that conversation is overdue, and it’s one we have every day at Soteria Pilates in Maitland.
Soteria Pilates · Maitland 9220 S US Highway 1792, Maitland, FL 32751 · 321-972-5095
| Key Takeaways |
| Perimenopause causes measurable insulin resistance, metabolic slowdown, and appetite dysregulation, not just hormonal symptoms |
| GLP-1s address several of the exact metabolic mechanisms disrupted by menopause |
| Without resistance training, 25 to 40% of weight lost on a GLP-1 can be muscle, not fat |
| Pilates-based strength training at Soteria Pilates in Maitland provides the progressive load needed to preserve muscle and bone during GLP-1 treatment |
| Resistance training improves insulin sensitivity independently: working alongside, not just with, the medication |
FAQ
Q: Why are GLP-1s being prescribed to women over 45?
A: GLP-1 receptor agonists address insulin resistance, appetite dysregulation, and metabolic dysfunction, all of which are directly worsened by the hormonal changes of perimenopause and menopause. They are increasingly prescribed to women in this age group for clinical metabolic reasons, not solely for weight loss.
Q: Do GLP-1s help with menopause weight gain?
A: Yes, by improving insulin sensitivity and reducing appetite, GLP-1s address two of the primary drivers of weight gain during perimenopause. However, they work best when paired with resistance training and adequate protein to prevent muscle loss alongside fat loss.
Q: What exercise should I do while taking Ozempic or Wegovy?
A: Resistance training 2 to 3 times per week is the most evidence-supported recommendation. Pilates-based strength training is particularly well-suited for women over 45: it is joint-protective, scalable to energy levels, and directly addresses the muscle and bone loss risks associated with GLP-1 use.
Q: Can GLP-1s cause muscle loss in women over 45?
A: Without resistance training, studies show that 25 to 40% of weight lost on GLP-1 medications can be lean muscle mass rather than fat. This is why structured strength training is considered essential alongside GLP-1 treatment for women in this age group.
Q: Is there a Pilates studio in Maitlands that works with women on GLP-1s?
A: Yes, Soteria Pilates in Maitland offers Pilates-based strength training programmes designed specifically for women over 45 navigating GLP-1 treatment, menopause, and the muscle and bone loss risks that come with both. The studio is located at 9220 S US Highway 1792, Maitland, FL 32751 and can be reached at 321-972-5095.